The lowest effective dose is a real concept with almost no data behind it
What the labels permit, what clinicians do, and the size of the gap between them.
The Ledger
Page 5 of 25 of this archive, newest first.
Page 5
The United Kingdom declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Brazil caps exenatide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The submitted sample: the weakest link in the whole system
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
Portugal caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Singapore declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Custody, condition and the temperature nobody logged
Chain of custody, in a regulated setting, begins at sampling. Here it begins when the package arrives.
The supply gap as a clinical event
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
South Korea caps tirzepatide prescribing to 24 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What SURMOUNT-1 tells us about maintenance, and what it does not
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Saudi Arabia declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Sending the same vial twice, under two names
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
Australia caps exenatide prescribing to 21 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Australia declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The badge is about a sample. The listing is about a product.
Lot-level verification with a public report is a real and achievable thing. It exists in this market, on a minority of listings.
Canada caps exenatide prescribing to 9 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The supply gap as a clinical event
A supply interruption is a discontinuation with no notice, no taper and no plan. That is a distinct clinical situation.
Side effects, cost, supply, target: four reasons with four trajectories
A supply interruption is a discontinuation with no notice, no taper and no plan. That is a distinct clinical situation.
The United Arab Emirates declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The submitted sample: the weakest link in the whole system
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.